
- /
- Supported exchanges
- / F
- / HG6.F
Mayne Pharma Group Limited (HG6 F) stock market data APIs
Mayne Pharma Group Limited Financial Data Overview
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women's Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Mayne Pharma Group Limited data using free add-ons & libraries
Get Mayne Pharma Group Limited Fundamental Data
Mayne Pharma Group Limited Fundamental data includes:
- Net Revenue: 388 M
- EBITDA: 18 797 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2017-12-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mayne Pharma Group Limited News

Mayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ADELAIDE, Australia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the ...


While institutions invested in Mayne Pharma Group Limited (ASX:MYX) benefited from last week's 12% gain, retail investors stood to gain the most
Key Insights Mayne Pharma Group's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 23 investors have a majority ...

Shawn O’Brien Buys Handful Of Shares In Mayne Pharma Group
Even if it's not a huge purchase, we think it was good to see that Shawn O’Brien, the CEO, MD & Director of Mayne Pharma Group Limited (ASX:MYX) recently shelled out AU$141k to buy stock, at AU$3.80...

Strong week for Mayne Pharma Group (ASX:MYX) shareholders doesn't alleviate pain of five-year loss
This week we saw the Mayne Pharma Group Limited (ASX:MYX) share price climb by 10%. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Fi...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.